Connect to share and comment

China and India face huge cancer burden

China and India are facing a cancer crisis, with smoking, belated diagnosis and unequal access to treatment all causing large-scale problems, experts said on Friday. In a major report, published in The Lancet Oncology, more than 40 specialists warn that Asia's big two emerging giants are facing huge economic and human costs from the disease. In China, cancer now accounts for one in every five deaths, ranking second only to cardiovascular disease as the most common cause of mortality, according to the study.

Fertility drugs not tied to long term breast cancer risk

By Andrew M. Seaman NEW YORK (Reuters Health) - Despite concerns and some evidence that fertility treatments increase a woman's chances of developing breast cancer, a large, long term study finds no added risk. Nearly 10,000 women who received drugs to stimulate ovulation were no more likely to develop breast cancer during 30 years of follow-up than those who never used the drugs, researchers report.

Novartis says lung cancer patients respond to drug in study

ZURICH (Reuters) - Novartis said late on Wednesday that a majority of patients given a development drug against non-small cell lung cancer had responded to the treatment, according to study results published in the New England Journal of Medicine. The Basel-based drugmaker's LDK378 has been declared a "breakthrough therapy", a designation created by the U.S. Food and Drug Administration in 2012 to help speed drugs to market that treat serious or life-threatening conditions and are deemed likely to work better than existing treatments.

Could half of all breast cancers be prevented?

By Anne Harding NEW YORK (Reuters Health) - If girls and women of all ages adopted healthier lifestyle behaviors and the highest-risk women took preventive drugs like tamoxifen, the authors of a new report say fully half of breast cancers in the U.S. might be avoided.

Endocyte shares soar after cancer drug gets EU backing

By Vrinda Manocha (Reuters) - Endocyte Inc's shares more than doubled after the company said its cancer drug was recommended for conditional approval in Europe for ovarian cancer and that the drug improved survival rates in lung cancer patients. Analysts said investors were not really expecting European regulators to back the drug.

Black-white disparities widening in U.S. breast cancer deaths

By C.E. Huggins NEW YORK (Reuters Health) - In the largest cities in the U.S., death rates from breast cancer have dropped across the board over 20 years, but far less so for black women than whites, according to a new analysis. The widening survival gap is likely due to differences in the quality of healthcare and access to it, researchers contend, because health factors alone cannot explain the changes over two decades.

Archaeologists discover earliest example of human with cancer

By Kate Kelland LONDON (Reuters) - British archaeologists have found what they say is the world's oldest complete example of a human being with metastatic cancer and hope it will offer new clues about the now common and often fatal disease. Researchers from Durham University and the British Museum discovered the evidence of tumors that had developed and spread throughout the body in a 3,000-year-old skeleton found in a tomb in modern Sudan in 2013.

3,200-year-old skeleton found with cancer

Archaeologists have found the 3,200-year-old skeleton of a man with a spreading form of cancer, the oldest example so far of a disease often associated with modern lifestyles, scientists said Monday. The remains of a man believed to be aged between 25 and 35 were found last year in a tomb in Sudan on the banks of the River Nile by a student at Durham University in northeast England.

Court denies Myriad motion to block rival genetic tests

(Reuters) - Myriad Genetics Inc said a U.S. court denied its motion to temporarily stop rival Ambry Genetics Corp from selling products similar to Myriad's gene-based cancer test, the latest setback for the diagnostics company. Myriad's shares fell 12 percent before the bell on Tuesday. Myriad's problems started last June when the U.S. Supreme Court ruled that the company could not patent naturally occurring human genes, curbing the company's monopoly over a type of gene-based cancer testing.

Brazil starts HPV vaccination program

Brazilian President Dilma Rousseff on Monday said the country was rolling out a vaccination program to protect five million 11-to 13-year-old girls against the human papilloma virus (HPV), which can cause cause cervical cancer. "The state has an obligation to protect all girls," Rousseff said as she inaugurated the program in Sao Paulo.
Syndicate content